AssetMark Inc
DNLI icon

AssetMark Inc’s Denali Therapeutics DNLI Stock Holding History

AssetMark Inc’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$127K Buy
6,137
+921
+18% +$21.6K ﹤0.01% 1586
2026
Q2 		$134K Buy
5,216
+17
+0.3% +$349 ﹤0.01% 1547
2026
Q1 		$100K Buy
5,199
+12
+0.2% +$239 ﹤0.01% 1539
2025
Q4 		$85.6K Buy
5,187
+1,250
+32% +$21.1K ﹤0.01% 1548
2025
Q3 		$57.2K Buy
3,937
+317
+9% +$4.56K ﹤0.01% 1590
2025
Q2 		$50.6K Buy
3,620
+435
+14% +$6.12K ﹤0.01% 1562
2025
Q1 		$43.3K Sell
3,185
-494
-13% -$9.46K ﹤0.01% 1476
2024
Q4 		$75K Sell
3,679
-129
-3% -$3.3K ﹤0.01% 1307
2024
Q3 		$111K Buy
3,808
+580
+18% +$14.4K ﹤0.01% 1133
2024
Q2 		$75K Sell
3,228
-86
-3% -$1.65K ﹤0.01% 1159
2024
Q1 		$68K Sell
3,314
-236
-7% -$4.44K ﹤0.01% 1111
2023
Q4 		$76.2K Buy
3,550
+1,402
+65% +$27.8K ﹤0.01% 1078
2023
Q3 		$44.3K Buy
2,148
+707
+49% +$17.9K ﹤0.01% 1118
2023
Q2 		$42.5K Buy
1,441
+669
+87% +$18.8K ﹤0.01% 1118
2023
Q1 		$17.8K Buy
772
+198
+34% +$5.45K ﹤0.01% 1200
2022
Q4 		$16K Buy
574
+136
+31% +$4.05K ﹤0.01% 1242
2022
Q3 		$13K Buy
+438
New +$14.2K ﹤0.01% 1196

Other funds holding DNLI

Temasek Holdings
Temasek Holdings Singapore $36.7B AUM 6.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

AssetMark Inc's DNLI Position: Q3 2026 in Review

AssetMark Inc increased its Denali Therapeutics (DNLI) stake by 18% in Q3 2026, buying an estimated $21.6K and bringing the position to 6,137 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #1586.

AssetMark Inc first reported a position in DNLI in Q3 2022 and has held it in 17 quarters since. The position peaked at $134K in Q2 2026. 108 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

  • AssetMark Inc held 6,137 shares of Denali Therapeutics worth $127K as of Q3 2026.
  • AssetMark Inc bought 921 Denali Therapeutics shares in Q3 2026, an estimated $21.6K.
  • Denali Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #1586 holding.
  • AssetMark Inc first reported a position in Denali Therapeutics in Q3 2022 and has held it in 17 quarters since.
  • AssetMark Inc's Denali Therapeutics position peaked at $134K in Q2 2026.
  • 108 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.